TB Alliance Appoints Dr. Soraya Madani as Senior Vice President, Program and Alliance Management
New York, NY (August 29, 2025) – TB Alliance announced the appointment of Dr. Soraya…
TB Alliance Congratulates Dr. Kathleen Schostack on Her Retirement
As Senior Vice President of Program and Alliance Management, Dr. Schostack played a vital role…
Bangladesh TB Leaders Build Momentum for Shorter, Safer Drug-Resistant Tuberculosis Treatment
Capacity building program in the Philippines empowers Bangladesh NTP managers to scale up BPaL and…
New Study Affirms Financial and Public Health Advantages of Treating Drug-Resistant TB with BPaL-Based Regimens in India
A new economic evaluation has added powerful evidence to the already strong case for wide,…
TB Alliance’s DR-TB Treatment Rollout Recognized by WHO as Model for Responsible & Effective Antibiotic Introduction
The World Health Organization’s (WHO) new guidance on Country Preparedness for the Introduction and Appropriate…
Indonesian Ministry of Health and TB Alliance Enter Strategic Partnership to Advance Innovations in TB and Mycobacterial Diseases
Collaboration Aims to Strengthen Health Systems and Accelerate Development of Next-Generation Treatments JAKARTA (July 30,…
TB Experts Rally Around New, Shortened TB Treatments
Regional meeting in Peru convened by PeerLINC, a global peer-to-peer initiative, brings together 20 countries…
Price of Key DR-TB Medicine Drops 25% as TB Alliance’s Multi-Manufacturer Strategy Expands Access
TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving…
Afrigen Biologics and Vaccines: A Catalyst in mRNA Technology and LMIC Capacity Strengthening
Afrigen Biologics and Vaccines embodies the spirit of equitable healthcare innovation, scientific advancement, and regional…